Role of P-Glycoprotein in Refractoriness of Seizures to Antiepileptic Drugs in Lennox-Gastaut Syndrome

被引:8
|
作者
Kumar, Achal [1 ]
Tripathi, Deepak [2 ]
Paliwal, Vimal Kumar [1 ]
Neyaz, Zafar [3 ]
Agarwal, Vikas [2 ]
机构
[1] SGPGIMS, Dept Neurol, Lucknow 226014, Uttar Pradesh, India
[2] SGPGIMS, Dept Clin Immunol, Lucknow 226014, Uttar Pradesh, India
[3] SGPGIMS, Dept Radiodiag, Lucknow 226014, Uttar Pradesh, India
关键词
Lennox-Gastaut syndrome; refractory epilepsy; P-glycoprotein; multidrug resistance gene; MEDICALLY INTRACTABLE EPILEPSY; FOCAL CORTICAL DYSPLASIA; MULTIDRUG TRANSPORTERS; RESISTANCE PROTEINS; GENE-EXPRESSION;
D O I
10.1177/0883073814532545
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Mechanism of seizure refractoriness to antiepileptic drugs in children with Lennox-Gastaut syndrome is not known. Efflux of antiepileptic drugs due to increased expression/function of P-glycoprotein, a multidrug efflux transporter protein on the cell surface is a proposed mechanism. The authors studied the expression/function of P-glycoprotein on peripheral blood mononuclear cells of 29 children with Lennox-Gastaut syndrome, 23 children with other epilepsies, and 19 healthy children. The authors found a higher P-glycoprotein expression/function in Lennox-Gastaut syndrome, a higher percent positive cells as compared to children with other epilepsy (P < 0.001) and to healthy controls (P = 0.012), higher P-glycoprotein expression as compared to healthy controls (P = 0.003), a higher total P-glycoprotein expression (relative florescence intensity x percent positive cells) as compared to children with other epilepsies (P < 0.001) and healthy controls (P < 0.001), and a higher P-glycoprotein function as compared to children with other epilepsies (P = 0.001) and healthy controls (P = 0.002). These findings may explain seizure refractoriness to anti-epileptic drugs in Lennox-Gastaut syndome.
引用
收藏
页码:223 / 227
页数:5
相关论文
共 50 条
  • [41] Safety and long-term effectiveness of new antiepileptic drugs in symptomatic lennox-gastaut syndrome
    Pauletto, G.
    Cecotti, L.
    Bassetti, M.
    Gigli, G.
    Bergonzi, P.
    EPILEPSIA, 2006, 47 : 121 - 121
  • [42] FELBAMATE IN LENNOX-GASTAUT SYNDROME
    SEVERI, S
    BONARDI, R
    CAMPOSTRINI, R
    GALLI, R
    MUSCAS, GC
    VATTI, GP
    EPILEPSIA, 1995, 36 : S147 - S147
  • [43] Cannabidiol in the Lennox-Gastaut Syndrome
    Feng, Linda
    Hoyland, Lisa
    Poulton, Alison
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (08): : 794 - 794
  • [44] Lennox-Gastaut syndrome: An overview
    Ramanathan, Ramnath Santosh
    Ahluwalia, Tina
    Sharma, Ankush
    JOURNAL OF PEDIATRIC NEUROSCIENCES, 2010, 5 (01) : 86 - +
  • [45] Lennox-Gastaut Syndrome: In a Nutshell
    Jahngir, Muhammad Umair
    Ahmad, Malik Qistas
    Jahangir, Memoona
    CUREUS, 2018, 10 (08):
  • [46] OUTCOME OF THE LENNOX-GASTAUT SYNDROME
    FREMION, A
    EMERSON, R
    FREEMAN, JM
    NIEDERMEYER, E
    VINING, EPG
    ANNALS OF NEUROLOGY, 1980, 8 (02) : 229 - 229
  • [47] The nosology of Lennox-Gastaut syndrome
    Hirt, HR
    NERVENARZT, 1996, 67 (02): : 109 - 122
  • [48] Treatment of Lennox-Gastaut syndrome
    Hancock, Eleanor C.
    Cross, J. Helen
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (02):
  • [49] LENNOX-GASTAUT SYNDROME IN THE ELDERLY
    BENBADIS, SR
    DINNER, DS
    CLINICAL ELECTROENCEPHALOGRAPHY, 1994, 25 (04): : 142 - 147
  • [50] LENNOX-GASTAUT SYNDROME IN ADULTHOOD
    ROGER, J
    REMY, C
    BUREAU, M
    OLLERDAURELLA, L
    BEAUMANOIR, A
    FAVEL, P
    DRAVET, C
    REVUE NEUROLOGIQUE, 1987, 143 (05) : 401 - 405